NCT06669000 Time Required to Dissolve Urate Deposits
| NCT ID | NCT06669000 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Gout |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-09-24 |
| Primary Completion | 2032-09-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2024-09-24 with a primary completion date of 2032-09-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Gout is characterized by episodes of acute arthritis of the lower limbs due to intermittent activation of innate immunity in the joints where urate crystals have formed. These crystals occur when serum urate (SUA) levels have been above 70 mg/L for many years. They can be dissolved by lowering SUA levels to at least 60 mg/L (treat-to-target - T2T - strategy). Once the crystals are dissolved, patients are no longer symptomatic and are considered to be in remission (treat-to-dissolve - T2D - strategy). The presence of crystals and their dissolution during treatment can be monitored by repeated ultrasound (US) scans of the feet and knees. The time required for complete dissolution varies from patient to patient. ReViGore40 is a cohort designed to i) determine the time to complete dissolution of urate deposits in joints when SUA levels are maintained below 40 mg/L, ii) determine the factors (clinical, biological, genetic) associated with the time required for complete dissolution of urate deposits within joints.
Eligibility Criteria
Inclusion Criteria: * Age over 18 years * Gout according to the ACR/Eular 2015 criteria * SUA levels greater than 60 mg/L * US score (MTP1s, knees) ≥2/24 * Informed consent Dated and signed voluntarily Exclusion Criteria: * Ongoing urate lowering therapy * Severe and uncontrolled diseases such as cancer, cardiovascular or neurovegetative diseases * Pregnant or breast-feeding women * No affiliation to the French National Social Security System
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06669000 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gout. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06669000 currently recruiting?
Yes, NCT06669000 is actively recruiting participants. Contact the research team at pascal.richette@aphp.fr for enrollment information.
Where is the NCT06669000 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06669000 clinical trial?
NCT06669000 is sponsored by Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 250 participants.